drugset
drugset / Trial / NCT00357305

Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders

NCT00357305 ↗

Phase 1 Completed 25 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of vorinostat when given together with cytarabine and etoposide in treating patients with relapsed or refractory acute leukemia or myelodysplastic syndromes or myeloproliferative disorders. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cytarabine and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving vorinostat together with cytarabine and etoposide may kill more cancer cells.

Timeline

Start
2006-05
Primary completion
2011-11
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Vorinostat Small molecule — Oral
Background Cytarabine Small molecule — Intravenous
Background Etoposide Small molecule — Intravenous

Indications

acquired polycythemia vera acute basophilic leukemia acute erythroid leukemia acute lymphoblastic leukemia acute megakaryoblastic leukemia in adult acute myeloblastic leukemia with maturation acute myeloblastic leukemia without maturation acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) acute myeloid leukemia with minimal differentiation acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia, t(16;16)(p13.1;q22) acute myelomonocytic leukemia M4 acute promyelocytic leukemia adult acute monocytic leukemia atypical chronic myeloid leukemia, BCR-ABL1 negative blast phase chronic myelogenous leukemia, BCR-ABL1 positive chronic eosinophilic leukemia chronic myelomonocytic leukemia chronic neutrophilic leukemia essential thrombocythemia leukemia, myeloid, accelerated-phase myelodysplastic syndrome myeloproliferative neoplasm, unclassifiable primary myelofibrosis